The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China
Objective: Due to the initiation of the priority review program in China, many antitumor drugs have been approved for marketing based on phase II clinical trials and short-term surrogate endpoint indicators. This study used approved targeted drugs for the treatment of non-small-cell lung cancer (NSC...
Saved in:
Main Authors: | Mingjun Rui (Author), Zijing Wang (Author), Zhengyang Fei (Author), Yao Wu (Author), Yingcheng Wang (Author), Lei Sun (Author), Ye Shang (Author), Hongchao Li (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
by: Yingcheng Wang, et al.
Published: (2021) -
Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
by: Pingyu Chen, et al.
Published: (2022) -
Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma
by: Pingyu Chen, et al.
Published: (2024) -
Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints
by: Wenbo Zhu, et al.
Published: (2017) -
Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)